65645-33-2

Usage

Uses

Used in Organic Synthesis:
S-(-)-α-Methyl-p-aminobenzylamine is utilized as a key intermediate in organic synthesis for the preparation of a wide range of organic molecules. Its unique structural features allow for the development of complex molecular architectures through various chemical reactions.
Used in Pharmaceutical Research:
In the pharmaceutical industry, S-(-)-α-Methyl-p-aminobenzylamine serves as a valuable building block for the synthesis of novel pharmaceutical compounds. Its chiral nature enables the creation of enantiomerically pure drugs, which is crucial for ensuring the desired therapeutic effects and minimizing potential side effects.
Used as a Chiral Ligand in Asymmetric Catalysis:
S-(-)-α-Methyl-p-aminobenzylamine is employed as a chiral ligand in asymmetric catalysis, a technique that allows for the selective synthesis of enantiomers. This application is vital for the production of enantiomerically pure compounds, which are essential in various pharmaceutical and chemical applications.
Used as a Reagent for the Preparation of Chiral Compounds:
S-(-)-a-Methyl-p-aminobenzylamine also functions as a reagent in the preparation of chiral compounds, which are important in various fields, including drug development, where the stereochemistry of a molecule can significantly influence its biological activity and pharmacokinetics.
Used in Research and Development of New Drugs:
S-(-)-α-Methyl-p-aminobenzylamine is extensively used in the research and development of new drugs, contributing to the discovery and optimization of potential therapeutic agents. Its presence in the catalogs of various chemical suppliers underscores its importance and accessibility for researchers in the field.

Upstream product

• 38063-81-9 p-aminoacetophenone oxime 
• 99-92-3 p-aminobenzophenone 
• 262368-44-5 (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester 
• 4187-53-5 (R)-2-methyl-p-nitrobenzylamine 
• 132873-57-5 R-alpha-methyl-4-nitrobenzylamine hydrochloride 
• 694529-38-9 (R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester 
• 57233-86-0 d-(+)-α-methyl-4-nitrobenzylamine hydrochloride 
• 132873-57-5 (S)-(-)-α-methyl-4-nitrobenzylamine hydrochloride 
• 35588-60-4 p-chloro-(R,S)-1-phenylethylamine 
• 100-19-6 (4-nitrophenyl)ethanone 
• 42142-15-4 1-(4-nitro-phenyl)-ethylamine 

Relevant academic research and scientific papers

Microwave-Enhanced Asymmetric Transfer Hydrogenation of N-(tert-Butylsulfinyl)imines

Microwave irradiation has considerably enhanced the efficiency of the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in isopropyl alcohol catalyzed by a ruthenium complex bearing the achiral ligand 2-amino-2-methylpropan-1-ol. In addition to shortening reaction times for the transfer hydrogenation processes to only 30 min, the amounts of ruthenium catalyst and isopropyl alcohol can be considerably reduced in comparison with our previous procedure assisted by conventional heating, which diminishes the environmental impact of this new protocol. This methodology can be applied to aromatic, heteroaromatic and aliphatic N-(tert-butylsulfinyl)ketimines, leading, after desulfinylation, to the expected primary amines in excellent yields and with enantiomeric excesses of up to 96 %. Microwave irradiation promotes the asymmetric transfer hydrogenation of N-(tert-butylsulfinyl)imines in 2-propanol catalysed by a ruthenium complex bearing an achiral β-amino alcohol as ligand. After desulfinylation, α-branched primary amines containing aromatic, heteroaromatic and aliphatic substituents are obtained in excellent yields and with enantiomeric excesses of up to 96 %.

NOVEL CATALYSTS

The present invention provides novel compounds and ligands that are useful in transition metal catalyzed cross-coupling reactions. For example, the compounds and ligands of the present invention are useful in palladium or gold catalyzed cross-coupling reactions.

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and in the claims. The invention also relates to the use thereof for treat

COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The invention relates to substituted 1,2-ethylenediamines of general formula (I), wherein the radicals R1-R13, A, B, L and i are as defined in the description and the claims. The invention also relates to the use thereof for treating Alzheimer's disease (AD) and similar diseases.

Asymmetric synthesis of chiral primary amines by transfer hydrogenation of N -(tert -Butanesulfinyl)ketimines

(Figure presented) The diastereoselective reduction of (R)-N-(tert- butanesulfinyl)ketimines by a ruthenium-catalyzed asymmetric transfer hydrogenation process in isopropyl alcohol, followed by desulfinylation of the nitrogen atom, is an excellent method to prepare highly enantiomerically enriched α-branched primary amines (up to >99% ee) in short reaction times (1-4 h). (1S,2R)-1-Amino-2-indanol has been shown to be a very efficient ligand to perform this transformation. Ketimines bearing either an aryl or a heteroaryl group and an alkyl group as substituents of the iminic carbon atom are very good substrates for this process. The reduction of a dialkyl ketimine could also be achieved, affording the expected amine with moderate optical purity (69% ee). Some amines which are precursors of very interesting biologically and pharmacologically active compounds have been prepared in excellent yields and enantiomeric excesses.

A P,N-Ligand for palladium-catalyzed ammonia arylation: Coupling of deactivated aryl chlorides, chemoselective arylations, and room temperature reactions

(Figure Presented) Amazing ammonia: A new air-stable P,N-ligand (Mor-DalPhos) is reported that enables the palladium-catalyzed crosscoupling of ammonia to a variety of aryl chloride and aryl tosylate substrates with high chemoselectivity and, for the first time, at room temperature (see scheme; Ad = adamantyl, Ts=para-toluenesulfonyl).

SIGNALING PROTEIN MODULATORS AS THERAPEUTIC AGENTS

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments

Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 μM which is 10-fold more potent than capsazepine.